ARTELO BIOSCIENCES INC C/WTS 25/06/2024(TO PUR COM) ARTLW 深 沪
已收盘 06-17 16:00:00 美东时间
0.0056
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0056
- 总市值 1.87万
- 52周最高 0.1498
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.005
- 委 比 0.00%
- 总股本 334.74万
- 历史最高 1.25
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.005
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Artelo Biosciences Announces Two Presentations Supporting Development Of ART26.12, Its Selective Fatty Acid Binding Protein 5 Inhibitor
The presentations include results from the Phase 1 clinical study of ART26.12 as well as new biomarker analyses designed to identify indicators of target engagement and pharmacological activity in healthy volunteers. During the first of two presentations, Professor Saoirse E. O'Sullivan, Vice Presid...
06-29 20:48
Artelo Biosciences Presents Metabolite Identification And Profiling Data From Its FABP Inhibitor Candidate ART26.12; Tracks Three Metabolites From Plasma Of Healthy Volunteers Given Single 900 Mg Oral Dose Of ART26.12
Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, announces that Myles Osborn, Lead Medicina...
06-10 19:40
Artelo Biosciences reports favorable human metabolite profile for ART26.12 in completed SAD trial
Artelo Biosciences reports favorable human metabolite profile for ART26.12 in completed SAD trial Artelo Biosciences presented new human metabolite profiling results for pain candidate ART26.12 at a London DMPK and medicinal chemistry conference. Data came from plasma samples in a recently completed
06-10 19:38
Artelo Biosciences Launches Flexible At-The-Market Offering
The latest announcement is out from Artelo Biosciences ( ($ARTL) ). On May 26, ...
05-28 05:37
Why Semtech Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
Semtech Corp (SMTC) reported strong Q1 financial results, beating analysts' estimates. Shares rose 7% in pre-market trading as Q2 guidance exceeded expectations.
05-27 17:10
Artelo Biosciences Files Prospectus To Offer Up To $6.53M In Common Stock Via H.C. Wainwright
-SEC Filing
05-27 04:55
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Sunshine Biopharma (NASDAQ:SBFM) stock moved upwards by 635.6% to $2.0...
05-18 20:05
Artelo Biosciences Ends ATM Offering, Shifts Financing Strategy
An announcement from Artelo Biosciences ( ($ARTL) ) is now available. On May 11...
05-16 05:28
Artelo Biosciences shares are trading lower after the company reported worse-than-expected Q1 EPS results.
Artelo Biosciences shares are trading lower after the company reported worse-th...
05-15 23:16
Artelo Biosciences Q1 EPS $(4.00) Misses $(1.57) Estimate
Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(4.00) per share which missed the analyst consensus estimate of $(1.57) by 154.78 percent. This is a 69.14 percent increase over losses of $(12.96) per share
05-15 04:56
